A U.S. federal judge rejected Swiss drugmaker Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from ...

Novartis AG (NVS) reports robust sales and income growth, announces a $10 billion share buyback, and navigates competitive ...

The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...

Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...

NVS beats on Q2 earnings, raises 2025 income outlook on strong drug sales, but Cosentyx miss and CFO exit weigh on shares.

Novartis could soon face generic competition for Entresto after judge's ruling.

Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

The title of the story has been corrected to reflect that the outlook was raised, instead of the erroneous “outlook cut” ...

Novartis is launching a $10 billion share buyback to be completed by year-end 2027 as new drug launches accelerate. | ...

Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio. The Swiss pharma firm is looking to shift reliance away from its ...

In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO ...

Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key products, including its breast cancer drug Kisqali, during a strong second quarter ...